Ann Arbor, MI (PRWEB) March 25, 2011
CUREM Research Partners has been contracted to conduct Clinical Monitoring, Study Management and Data Management services on the Phase 2 clinical study of ETC-1002 for Esperion Therapeutics.
Esperion reports that ETC-1002 is a novel small molecule compound with a favorable safety profile that in earlier trials demonstrated statistically significant lowering of LDL-C in mildly dyslipidemic subjects.
The 12-week, multi-site, randomized, double-blind, placebo controlled study will enroll 176 patients with hypercholesterolemia, with or without high triglycerides, to assess the role of ETC-1002 in lipid regulation (LDL-C and triglycerides).
CUREM will provide Study Management, Clinical Monitoring and Data Management support through study completion to ensure timely and accurate data reporting. “Our core team has a strong lipid background having worked together on Lipitor® for over 7 years,” says CUREM Research founder and principal consultant, Wendy Eggleston, M.S. “We are excited to continue our relationship with Esperion and work in the next generation of cardiovascular compounds.”
According to Esperion founder and CEO, Roger Newton, P.h.D. “Esperion has worked with the staff at CUREM Research for several years and we find their technical depth, customer service, attention to detail and cost competiveness to be outstanding. Esperion is delighted to have the support of CUREM as we develop treatments for cardio-metabolic diseases that remain the leading cause of morbidity and mortality among men and women worldwide.”
For more information on CUREM Research visit http://www.curemresearch.com or call 734-913-7979.
# # #